Clinical Data ASCO: BMS hails “compelling” phase 3 celmod readout PharmaphorumBristol Myers Squibb has high hopes for its celmod drugs, and a phase 3 trial for mezigdomide in multiple myeloma at ASCO26 has delivered the goods.OncologyRead full story pharminent May 29, 2026 (Last updated: May 29, 2026) Pharmaphorum Bristol Myers Squibb has high hopes for its celmod drugs, and a phase 3 trial for mezigdomide in multiple myeloma at ASCO26 has delivered the goods. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peersNext: Next Post Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
